NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

Analysts Doug Schenkel and Shaun Rodriguez wrote in a research note published today that concerns about competition and a lack of "significant near-term catalysts" has led them to downgrade Luminex. "We believe competitive pressures have intensified for [Luminex's] molecular diagnostics franchise and anticipate pronounced share loss in [Respiratory Virus Panel] and a muted [Gastrointestinal Pathogen Panel] launch as a result."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.